An mRNA, a composition and its uses

By encapsulating mRNA in lipid nanoparticles to target hepatic sinusoidal endothelial cells, expressing the Bet v 1 protein antigenic epitope, and inducing regulatory T cells, the safety and compliance issues of existing allergy therapies are resolved, and effective treatment of cross-reactions to birch pollen and food allergies is achieved.

CN123063408APending Publication Date: 2026-11-10ZHEJIANG MARINA BIOTECHNOLOGY CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202510584392.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-05-07
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing allergen immunotherapy has problems such as safety risks, poor compliance, insufficient long-term efficacy and limited treatment scope, especially in relieving cross-reactions between birch pollen allergy and food allergy.

Method used

Using mRNA encapsulated in mannose-modified lipid nanoparticles, the drug targets hepatic sinusoidal endothelial cells, expresses the antigenic epitope of Bet v1 protein, induces the generation of Foxp3+ regulatory T cells, inhibits Th2 immune responses, reduces IgE production, and prevents mucosal inflammation through the presentation of MHC-II molecules.

Benefits of technology

It achieves safe, convenient, and precise treatment, covering cross-reactions between birch pollen and food allergies, reducing allergic reactions, and is suitable for the prevention or treatment of allergic diseases such as allergic rhinitis and hay fever.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123063408A_ABST
    Figure CN123063408A_ABST
Patent Text Reader

Abstract

This invention discloses an mRNA, a composition, and their uses, belonging to the field of biomedicine. The mRNA contains an open reading frame encoding a Bet v1 protein, which has an epitope peptide comprising one or more of the amino acid sequences shown in SEQ ID NO: 1-6. This invention also discloses a composition comprising a vector and the mRNA or the DNA molecule. The mRNA or composition of this invention can be translated in LSECs, and the epitope peptide enters the MHC-II antigen processing pathway and is presented to CD4. + T cells induce Foxp3 + The generation of regulatory T cells (Tregs) triggers tolerance responses to allergens; in addition, it can inhibit Th2 cells and reduce the levels of IgE, IL-4, IL-5 and IL-13, thereby effectively controlling allergic reactions and showing great application potential.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomedicine, specifically to an mRNA, a composition, and its uses. Background Technology

[0002] Birch pollen allergy is one of the major allergens in Northern and Central Europe during the spring and summer. Over 95% of birch pollen allergy sufferers have specific IgE antibodies against the major allergen, Bet v1. Birch pollen allergy in adolescents and adults is often closely related to food allergies triggered by Rosaceae fruits (such as apples, cherries, and apricots), nuts (such as hazelnuts), and Apiaceae vegetables (such as celery and carrots). Approximately 70% of birch pollen allergy sufferers develop oral allergy syndrome (OAS), characterized by localized immediate hypersensitivity reactions such as irritation, itching, and swelling of the lips and oral mucosa after contact with raw fruits and vegetables. Patients sensitive to the soybean allergen Glym4 (SAM22) may experience more severe systemic symptoms than OAS. The major birch allergen, Bet v1, plays a central role in the pathogenesis of "birch-fruit syndrome" by inducing cross-reactions—after the body is sensitized through the respiratory tract and produces Bet v1-specific IgE antibodies, these antibodies cross-react with structurally similar proteins in food. In addition to the cross-reactivity of humoral immunity, the study also confirmed that Bet v1 homologs in apples and celery can induce cross-reactivity at the T cell level and identified dominant T cell epitopes with high sequence homology to Bet v1.

[0003] Existing immunotherapies: The core objective of allergen immunotherapy (AIT) is to reprogram the immune response by inducing regulatory T cells (Tregs) to transform the Th2-dominated IgE response into immune tolerance, thereby providing long-term symptom relief and reducing dependence on symptomatic drugs.

[0004] The main birch allergen, Bet v1, is highly homologous to proteins found in apples (Mal d 1), hazelnuts, celery, carrots, and soybeans. Its amino acid sequence at positions 142-156 (TLLRAVESYLLAHSD) is a dominant CD4+ T cell epitope, recognizable by over 60% of allergy sufferers. Targeting this conserved epitope holds promise for simultaneously alleviating respiratory and food allergy symptoms. Currently, the main clinical treatments are: 1) Subcutaneous immunotherapy (SCIT): Inducing immune tolerance through subcutaneous injection of escalating doses of allergen extract. While its efficacy is clear, it requires frequent, long-term visits (usually lasting 3-5 years) and carries the risk of serious adverse reactions such as anaphylactic shock. 2) Sublingual immunotherapy (SLIT): Patients can take allergen extract sublingually at home. Its efficacy is comparable to SCIT with fewer systemic reactions, but long-term daily use still affects adherence. 3) Epidermal immunotherapy (EPIT): Delivering allergens via skin patches. Clinical trials have shown that it can alleviate birch / grass pollen allergy symptoms, but 10% of patients may experience local skin reactions requiring intervention. 4) Mechanism of action: AIT works through the following pathways: inhibiting the activity of effector cells such as mast cells / basophils; blocking the release of histamine and cytokines; inducing the secretion of Tregs containing IL-10 / TGF-β, establishing a long-term tolerance state. Limitations of existing therapies: 1) Safety: SCIT may trigger severe allergic reactions; 2) Compliance: 3-5 year treatment courses lead to a high rate of treatment discontinuation; 3) Long-term efficacy: Insufficient real-world data; 4) Treatment breadth: All-allergen extracts may exacerbate allergic reactions and have limited coverage of cross-reactive food allergens.

[0005] Novel treatment strategies: 1) Multi-allergen recombinant proteins: Developing novel formulations covering multiple sensitizations, such as fusing allergens with human IgG Fcγ fragments to reduce IgE binding risk. 2) mRNA / DNA vaccines and peptide therapy: mRNA / DNA vaccines encoding allergen epitopes can precisely induce Tregs; synthetic peptides require optimized stability. 3) Adjuvant application: Adding adjuvants such as CpG to promote Th1 / regulatory immune responses, achieving high-efficiency treatment with low doses. 4) Long-term management: Studies indicate that high-risk individuals may require lifelong maintenance therapy. Exploration directions include: combination therapy with anti-IgE antibodies such as omalizumab; adjuvant therapy with traditional Chinese medicine compound formulas; and personalized treatment decision-making models.

[0006] Therefore, there is an urgent need for mRNA liposome particles that can improve safety and efficacy, provide convenient administration, and enable precise treatment to address cross-reactivity with inhaled / food allergens. Summary of the Invention

[0007] To address the problems existing in the prior art, this invention provides an mRNA, a composition, and their uses. The mRNA is encapsulated in lipid nanoparticles (LNPs) (mannose-modified) to form a composition that specifically targets hepatic sinusoidal endothelial cells (LSECs). The mRNA and composition of this invention express Bet v1 in vivo. 142-156 T cell epitopes are presented on MHC class II molecules, thereby inducing antigen-specific Foxp... 3+ The generation of regulatory T cells (Tregs). By utilizing the immune tolerance mechanism mediated by hepatic sinusoidal endothelial cells (LSECs), this invention can effectively suppress pathogenic Th2 immune responses, reduce the production of immunoglobulin IgE, and prevent allergen-induced inflammatory responses in the respiratory and gastrointestinal mucosa.

[0008] A first aspect of the present invention provides an mRNA comprising an open reading frame encoding a Bet v1 protein having an antigenic epitope peptide comprising one or more of the amino acid sequences shown in SEQ ID NO: 1-6.

[0009] The amino acid sequence of the Bet v 1 protein includes the sequence shown in SEQ ID NO:7.

[0010] The amino acid sequence of SEQ ID NO:1 contains EGFPFKYVKDRVDEV.

[0011] The amino acid sequence of SEQ ID NO:2 contains KYNYSVIEGGPIGDT.

[0012] The amino acid sequence of SEQ ID NO:3 contains GETLLRAVESYLLAH.

[0013] The amino acid sequence of SEQ ID NO:4 contains KAFILDGDNLFPKVA.

[0014] The amino acid sequence of SEQ ID NO:5 contains DHTNFKYNYSVIEGG.

[0015] The amino acid sequence of SEQ ID NO:6 contains KISNKYHTKGDHEVK.

[0016] Bet v1 protein is a major birch allergen identified in the pollen of *Betula pulcherrima* and *Betula pulcherrima*, and it induces IgE binding in over 95% of patients with birch pollen allergies. Immunoglobulin E (IgE) can cause type 1 hypersensitivity reactions, manifesting as allergic rhinitis, allergic conjunctivitis, hay fever, allergic asthma, bee venom allergy, and food allergies.

[0017] In some embodiments, the antigenic epitope peptide comprises one, two, three, four, five, or six of the above six amino acid sequences.

[0018] In some embodiments, the mRNA, from the 5' end to the 3' end, sequentially includes a 5' cap structure, a 5' untranslated region (5'UTR), an open reading frame (ORF), a 3' untranslated region (3'UTR), and a polyadenine tail (PolyA). In this invention, the polyadenine tail (PolyA) is the tail at the 3' end of most eukaryotic mRNAs and helps regulate mRNA stability, transport, and translation. Both the 5'UTR and 3'UTR are typically transcribed from genomic DNA and are elements of pre-mature mRNA. Characteristic structural features of mature mRNA (e.g., the 5' cap structure and the polyadenine tail (PolyA)) are typically added to the transcribed (pre-mature) mRNA during mRNA processing. The 5'UTR and 3'UTR sequences are independently derived from at least one of natural proteins and synthetic proteins; preferably, the natural protein includes any one of α-globulin, β-globulin, and the heat shock protein HSP70.

[0019] In some specific embodiments, the mRNA further includes KOZAK, and the mRNA comprises, from the 5' end to the 3' end, a 5' cap structure, a 5' untranslated region (5'UTR), KOZAK, an open reading frame (ORF), a 3' untranslated region (3'UTR), and a polyadenine tail (PloyA). In this invention, KOZAK is a nucleotide sequence located after the 5' cap structure of eukaryotic mRNA, which can bind to a promoter to mediate the translation initiation of mRNA containing the 5' cap structure. This corresponds to the SD sequence in prokaryotes.

[0020] In some specific embodiments, the mRNA also includes an invariant strand (e.g., Ii 1-80aa) fused upstream. The invariant strand is a molecular chaperone protein of the MHC-II molecule, whose main function is to assist in loading the antigen epitope peptide into the MHC-II molecule, thereby achieving antigen presentation.

[0021] In some implementations, the mRNA is either unmodified or modified.

[0022] In some embodiments, the modification is N1-methylpseudouridine substitute uridine.

[0023] A second aspect of the present invention protects a DNA molecule encoding mRNA as described above.

[0024] A third aspect of the present invention protects a composition comprising a vector and an mRNA or DNA molecule as described above.

[0025] In some embodiments, the vector includes a viral vector or a non-viral vector.

[0026] In some specific embodiments, the viral vector is selected from adeno-associated virus (AAV) vectors, adenovirus (Ad) vectors, lentivirus (LV) vectors, or herpes simplex virus (HSV) vectors; including but not limited to these.

[0027] In some more specific embodiments, the AAV vector includes one or more of the following: AAV1 vector, AAV2 vector, AAV5 vector, AAV6 vector, AAV8 vector, AAV9 vector, and AAVrh10 vector. AVV can be classified into AAV1, AAV2, AAV5, AAV6, AAV8, AAV9, and AAVrh10 according to different serotypes.

[0028] In some specific embodiments, the non-viral vector is selected from plasmids, cationic lipids, liposome nanoparticles (LNPs), liposomes, polymer-based vectors, virus-like particles, or extracellular vesicles.

[0029] In some more specific embodiments, the carrier is a liposome nanoparticle (LNP) selected from one or more of PEG-modified lipids, non-cationic lipids, sterols, and ionizable cationic lipids.

[0030] Preferably, the PEG-modified lipid is DSPE-PEG(2000)-mannose. In this invention, the mannose modification allows for targeting of CD206, thereby enabling the composition to bind to CD206 on hepatic sinusoidal endothelial cells (LSECs).

[0031] Preferably, the non-cationic lipid is 1,2-distearate-sn-glycerol-3-phosphocholine (DSPC).

[0032] Preferably, the sterol is cholesterol.

[0033] Preferably, the ionizable cationic lipid is selected from one or more of the compounds SM-102, 1,2-dioleoyl-3-trimethylammonium propane (DOTAP), or methyl 4-(N,N-dimethylamino)butyrate (dioleoyl) ester (DLin-MC3-DMA).

[0034] In some embodiments, the composition comprises liposome nanoparticles and mRNA, wherein the mRNA contains an open reading frame (ORF) encoding the Bet v1 protein. The composition formed from the liposome nanoparticles and mRNA has a particle size of 90–120 nm, a zeta potential of -5 to -10 mV, and an encapsulation efficiency >90%. It contains SM102, DSPC, cholesterol, DSPE-PEG(2000)-mannose, and mRNA, prepared using microfluidic mixing (e.g., the NanoAssemblr platform).

[0035] mRNA is unstable and carries a negative charge, while the cell membrane surface also carries a negative charge. Electrostatic repulsion makes it difficult for mRNA molecules to cross the cell membrane and enter the cell. Therefore, special modification or encapsulation delivery systems are required to achieve intracellular mRNA expression. Liposome nanoparticles (LNPs) have become the most popular delivery technology due to their high delivery efficiency and good safety. Therefore, mRNA is encapsulated within liposome nanoparticles to prepare a composition.

[0036] This application also provides a method for preparing mRNA, comprising the following steps:

[0037] 1) Construct a vector containing the target gene's ORF;

[0038] The vector contains the 5' cap structure, the 5' UTR (untranslated region), the target gene ORF, the 3' UTR, and the polyA tail.

[0039] 2) Amplify the constructed vector;

[0040] 3) The amplified vector is transcribed and purified to obtain mRNA;

[0041] 4) The target gene encodes the Bet v1 protein.

[0042] The 5' untranslated region (UTR) is the mRNA region that does not code for a polypeptide, located directly upstream (5') of the start codon (the first codon in the mRNA transcript translated by the ribosome). The 3' untranslated region (UTR) is the mRNA region that does not code for a polypeptide, located directly downstream (3') of the stop codon (the codon in the mRNA transcript that signals the termination of translation). Poly(A) is the 3' tail of most eukaryotic mRNAs and helps regulate mRNA stability, transport, and translation.

[0043] A fourth aspect of the present invention protects a protein comprising amino acids encoded by mRNA as described above.

[0044] A fifth aspect of the present invention protects an mRNA drug comprising the mRNA as described above, the composition as described above, the protein as described above, or the DNA molecule as described above.

[0045] The sixth aspect of the present invention protects the use of the mRNA, composition, protein, or DNA molecule described above in the preparation of a medicament for the prevention or treatment of allergic diseases.

[0046] In some embodiments, the allergic disease is selected from one or more of allergic rhinitis, atopic dermatitis, food allergy, oral allergy syndrome, drug allergy, hay fever, allergic conjunctivitis, eosinophilic pneumonia, allergic gastroenteritis, urticaria, photosensitivity, metal allergy, cat allergy, dust mite allergy, and asthma.

[0047] In some specific embodiments, the allergic disease is selected from oral allergy syndrome and hay fever. Preferably, the hay fever refers to an allergy to birch pollen or birch extract, and the birch pollen extract is selected from the group consisting of: natural Bet v, weeping birch BPE, river birch BPE, and poplar birch BPE.

[0048] In some embodiments, the mRNA or the composition is administered via intravenous or subcutaneous injection.

[0049] This application provides a method for preventing or treating allergic diseases, comprising administering to a test animal in need of such treatment an mRNA, or a composition, or a protein, or an mRNA drug, or a DNA molecule as described above.

[0050] The mRNA, composition, protein, DNA molecule, or mRNA drug of this invention can induce antigen-specific regulatory T cells to bind to CD206 on hepatic sinusoidal endothelial cells (LSECs) via LNPs (especially those modified with mannose). Subsequently, the mRNA is translated in the LSECs, and the antigenic epitope peptide enters the MHC-II antigen processing pathway and is presented to CD4+ T cells. On the one hand, it can induce the generation of Foxp3+ regulatory T cells (Tregs), which migrate to draining lymph nodes and mucosal tissues, thereby triggering a tolerance response to allergens. On the other hand, it can inhibit Th2 cells. This invention can reduce IgE production, lower the levels of IL-4, IL-5, and IL-13, and limit the degranulation of mast cells and eosinophils, thereby effectively controlling allergic reactions.

[0051] The present invention has the following beneficial effects:

[0052] 1) The mRNA, composition, protein, DNA molecule or mRNA drug of the present invention has specific tolerance, does not trigger IgE, and therefore will not cause hypersensitivity reaction; and the present invention covers food-related cross-reaction symptoms.

[0053] 2) The mRNA-containing composition of the present invention can deliver mRNA to liver sinusoidal endothelial cells (LSECs) by specifically binding mannose to mannose receptors on the surface of specific surfaces of liver sinusoidal endothelial cells (LSECs), thereby inducing immune tolerance through the antigen presentation function of liver sinusoidal endothelial cells.

[0054] 3) This invention significantly reduces the immunogenicity of mRNA and improves translation efficiency by replacing guanosine with N1-methylpseuuridine, thereby achieving non-inflammatory properties through the modified mRNA.

[0055] 4) The mRNA, composition, protein, DNA molecule or mRNA drug of the present invention can prevent or treat allergic diseases, and is particularly suitable for hay fever or oral allergy syndrome caused by birch pollen or birch extract, and therefore has great application prospects. Attached Figure Description

[0056] Figure 1 This is a flowchart illustrating the method for constructing multi-epitope birch allergen mRNA.

[0057] Figure 2 This is a basic structural diagram of mRNA.

[0058] Figure 3 This is a map of antigenic epitopes with high binding percentages in the Bet v1 protein. Detailed Implementation

[0059] To describe the present invention more specifically, the technical solution of the present invention will be described in detail below with reference to the accompanying drawings and specific embodiments. These descriptions are merely illustrative of how the present invention is implemented and do not limit the specific scope of the present invention. The scope of the present invention is defined in the claims.

[0060] Example 1: Prediction and Design of Antigenic Epitope Peptides

[0061] 1.1 Selection of Epitopes

[0062] Bet v1 protein sequence:

[0063] MGVFNYETEATSVIPAARLFKAFILDGDNLFPKVAPQAISSVENIEGNGGPGTIKKIS FPEGFPFKYVKDRVDEVDHTNFKYNYSVIEGGPIGDTLEKISNEIKIVATPDGGSILKISNK YHTKGDHEVKAEQVKASKEMGETLLRAVESYLLAHSDAYN(SEQ ID No.7)

[0064] MHC-II epitopes were searched using the Immune Epitope Database (IEDB) and the NetMHCIIpan 4.1EL tool. Table 1 (or Figure 3 The list includes epitopes with high binding percentiles.

[0065] Table 1

[0066]

[0067]

[0068] Table 2. Six Bet v1 epitope peptides were selected based on HLA allele coverage.

[0069]

[0070] The epitope peptides in Table 2 were reverse-translated into cDNA for mRNA design.

[0071] Table 3. Reverse translation of Bet v1 self-epitope peptides for therapeutic research

[0072]

[0073]

[0074] like Figure 1 The diagram shows a method for constructing a multi-epitope birch allergen mRNA developed to treat birch pollen allergies.

[0075] Using the epitope peptide sequences associated with birch pollen allergy summarized in Table 2, the first step is to reverse translate the epitope peptides into cDNA nucleotide sequences, as shown in Table 3. The splicing of these nucleotide sequences requires ligand sequences to enable peptide cleavage upon intracellular epitope release. Furthermore, the cDNA construct needs to possess a targeting sequence to allow the antigen to enter the MHC-II endosome compartment for peptide presentation to Treg precursor cells.

[0076] The protein subdomain of the invariant chain (Ii 1-80) (a molecular chaperone protein of MHC-II that facilitates the loading of peptides into MHC-II for antigen presentation) has been used to construct hybrids capable of entering MHC-II from the cytoplasm for presentation on CD4+ T cells. Therefore, Ii-OVA fusion has been shown to directly target the MHC-II processing pathway. Furthermore, the mRNA version of Ii 1-80 has been shown to be an effective targeting sequence for birch allergen epitope peptides, potentially useful for treating birch allergy.

[0077] Other targeting sequences include the transferrin receptor, a membrane glycoprotein that mediates iron uptake from the cell surface membrane after transferrin binding. Studies have shown that a fusion protein constructed from the membrane anchoring domain (amino acids Ii 1-80) of this receptor plus an MHC-II binding epitope from ovalbumin (aa 323-339) enables MHC-II entry and epitope expression on T cells. Against this background, the nucleotide sequence of the Ii 1-80 domain added upstream of the epitope peptide will be presented.

[0078] After designing the cDNA coding sequence, start and stop codons were added, such as... Figure 2 As shown.

[0079] In the next phase of the design, the integrated cDNA construct was codon-optimized to achieve optimal gene expression of the non-human cell tRNA library compared to human cells. This was accomplished using the GenScript online codon optimization tool.

[0080] Encoding antigen: The synthesized open reading frames encode the above 6 epitopes, with codon optimization for human expression. ATGGACGACCAGAGAGACCTGATCTCGAACCACGAGCAGCTGCCGATCCTGGGAAACAGACCACGGGAGCCAGAGCGCTGCTCCCGGGGGGCCCTGTACACAGGGGTATCAGTATTGGTGGCCCTGTTGCTGGCAGGCCAAGCTACCACTGCCTACTTCCTGTACCAGCAGCAAGGAAGACTGGACAAGCTCACCATCACAAGCCAGAATCTCCAGCTAGAATCTCTGAGGATGAAACTGGGCCCTGGTCCCGGCTTTCCAGAAGGCTTTCCTTTCAAGTATGTGAAAGACCGTGTGGATGAGGTGGACCATGGCCCTGGACCTGGCAACTTCAAAT ATAATTACAGCGTCATCGAAGGTGGCCCTATAGGAGACACTCTGGAGGGGCCTGGTCCTGGAGAGATGGGGGAGACCCTGCTTCGGGCTGTGGAGAGCTACCTGCTGGCCCACAGCGATGGCCCGGGCCCTGGCCTCTTTAAGGCCTTCATCCTGGATGGGGACAACCT CTTCCCCAAGGTGGCTCCACAGGGCCCCGGCCCAGGAGAAGTTGACCACACCAACTTTAAATACAACTACTCTGTCATTGAAGGAGGCCCCATTGGGCCCGGCCCTGGCATCCTGAAGATCTCTAATAAGTACCACACAAAAGGAGATCATGAGGTGAAGGCAGAATAA

[0081] GC content: 56.74%.

[0082] The coding sequence structure is as follows: 5' cap (CleanCap or ARCA) - 5' untranslated region (UTR) - Kozak sequence - invariant chain signal peptide - modified bases - 3' untranslated region (UTR) - Poly(A) tail

[0083] Among them, the Kozak sequence is used to optimize translation initiation; the invariant chain signal peptide (e.g., Ii 1-80aa) is fused upstream to guide the antigenic epitope peptide into the MHC-II processing pathway; the modified bases are replaced with N1-methylpseudouridine; 5' and 3' untranslated regions (UTRs) are included to enhance stability; and a Poly(A) tail of 100-120 nucleotides in length is included.

[0084] Length: <800nt.

[0085] Example 2: Lipid Nanoparticles (LNP)

[0086] In this embodiment, the mRNA screened in Example 1 was used to construct lipid nanoparticles. The core part includes three parts: ionizable cationic liposomes, auxiliary lipids, and targeting ligands. The nanoparticles were prepared using microfluidic mixing (e.g., the NanoAssemblr platform).

[0087] The ionizable lipid is SM102; the auxiliary lipids are DSPC and cholesterol; the targeting ligand is DSPE-PEG(2000)-mannose, used to target CD206.

[0088] The obtained lipid nanoparticles were tested, and the particle characterization is shown in Table 4 below.

[0089] Table 4

[0090] Particle size ζ-potential Encapsulation efficiency 90-120nm -5 to -10mV >90%

[0091] In this invention, a composition formed from lipid nanoparticles (LNPs) and mRNA binds to CD206 on hepatic sinusoidal endothelial cells (LSECs) via mannose-modified LNPs. Subsequently, the mRNA is translated within the LSECs, and the antigenic epitope peptide enters the MHC-II antigen processing pathway and is presented to CD4+ T cells. On one hand, it can induce the generation of Foxp3+ regulatory T cells (Tregs), which migrate to draining lymph nodes and mucosal tissues, thereby triggering a tolerance response to allergens. On the other hand, it can inhibit Th2 cells, reduce IgE production, lower the levels of IL-4, IL-5, and IL-13, and limit the degranulation of mast cells and eosinophils, thus effectively controlling allergic reactions. It can prevent or treat allergic diseases, and is particularly suitable for hay fever or oral allergy syndrome caused by birch pollen or birch extracts, thus showing great application potential.

[0092] While the present invention has been disclosed above, it is not limited thereto. Any person skilled in the art can make various modifications and alterations without departing from the spirit and scope of the invention; therefore, the scope of protection of the present invention should be determined by the scope defined in the claims.

Claims

1. An mRNA, characterized in that, It includes an open reading frame encoding the Bet v 1 protein, the Bet v 1 protein having an antigenic epitope peptide comprising one or more of the amino acid sequences shown in SEQ ID NO:1-6.

2. The mRNA as described in claim 1, characterized in that, From the 5' end to the 3' end, the mRNA sequentially includes a 5' cap structure, a 5' non-coding region, an open reading frame, a 3' non-coding region, and a polyadenine tail; And / or, the mRNA is unmodified or modified.

3. The mRNA as described in claim 1, characterized in that, The modification is N1-methylpseudouridine substitute uridine.

4. A DNA molecule encoding the mRNA as described in any one of claims 1-3.

5. A composition, characterized in that, Includes vectors and mRNA as described in any one of claims 1-3 or DNA molecules as described in claim 4.

6. The composition according to claim 5, characterized in that, The vector may include a viral vector or a non-viral vector; The viral vector is selected from adeno-associated virus vectors, adenovirus vectors, lentivirus vectors, or herpes simplex virus vectors; the non-viral vector is selected from plasmids, cationic lipids, liposome nanoparticles, liposomes, polymer-based vectors, virus-like particles, or extracellular vesicles.

7. The composition according to claim 6, characterized in that, The carrier is a liposome nanoparticle, which is selected from one or more of PEG-modified lipids, non-cationic lipids, sterols and ionizable cationic lipids. Preferably, the PEG-modified lipid is DSPE-PEG(2000)-mannose; Preferably, the non-cationic lipid is 1,2-distearate-sn-glycerol-3-phosphocholine (DSPC). Preferably, the sterol is cholesterol; Preferably, the ionizable cationic lipid is selected from one or more of the compounds SM-102, 1,2-dioleoyl-3-trimethylammonium propane (DOTAP), or methyl 4-(N,N-dimethylamino)butyrate (dioleoyl) ester (DLin-MC3-DMA).

8. A protein, characterized in that, It contains amino acids encoded by the mRNA as described in any one of claims 1-3.

9. An mRNA drug, characterized in that, The mRNA drug comprises the mRNA as described in any one of claims 1-3, the composition as described in any one of claims 5-7, the protein as described in claim 8, or the DNA molecule as described in claim 4.

10. Use of the mRNA as described in any one of claims 1-3, or the composition as described in any one of claims 5-7, or the protein as described in claim 8, or the DNA molecule as described in claim 4 in the preparation of a medicament for the prevention or treatment of allergic diseases.

Citation Information

Cited By

  • Multi-valent LSEC targeting mRNA lipid nanoparticle and its application

    EP4837592A1